

**TICILIMUMAB RESCINDED AND REPLACED BY TREMELIMUMAB.
PLEASE SEE TREMELIMUMAB ADOPTION STATEMENT.**

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN

TICILIMUMAB

PRONUNCIATION

tis i li mab

THERAPEUTIC CLAIM


treatment of cancer

CHEMICAL NAMES

- 1) Immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer
- 2) Immunoglobulin G2, anti-(human Cytotoxic T-lymphocyte protein 4 (CD 152 antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer

RESCINDED

STRUCTURAL FORMULA



MOLECULAR FORMULA
MOLECULAR WEIGHT

$C_{6500}H_{9974}N_{1726}O_{2026}S_{52}$
approximately 150 kDaltons

TRADEMARK

Unknown as yet

MANUFACTURER

Boehringer Ingelheim for Pfizer

CODE DESIGNATION

CP-675,206

CAS REGISTRY NUMBER

745013-59-6